{
  "docId": "019de076-f978-76c3-9c95-6b6ce7102162",
  "docSlug": "c02a1d1cb7557bc430cc8dc61cd27097",
  "documentTitle": "CG Oncology | IPO Presentation Deck | 45 slides",
  "authorId": "cg-oncology",
  "authorName": "CG Oncology",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 27,
  "pageCount": 45,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a process-flow layout to define the clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-f978-76c3-9c95-6b6ce7102162/27",
  "deckHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162",
  "deckJsonHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162.json",
  "deckAnchorHref": "/decks/019de076-f978-76c3-9c95-6b6ce7102162#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.31
      },
      "kind": "diagram",
      "text": "Population, Study Design / Regimen, Additional Endpoints",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "804a444c-da99-4c34-9e36-417cb237d2f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.06,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "Second induction course of weekly x 6 for non-responders at month 3. Maintenance course for complete responders starts at month 3 every 3 months (weekly x 3) until disease recurrence. Note: Patients undergo urine cytology and cystoscopy every 3 months for first 2 years; mandatory, site-directed biopsy at month 12.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f115679b-6ed3-4fab-8c1e-0e4368e1fb10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.33,
        "x": 0.37,
        "y": 0.49
      },
      "kind": "list",
      "text": "Cohort A = BCG-exposed NMIBC (Induction, Second induction, Maintenance); Cohort B = BCG-naïve NMIBC (Same regimen)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12c4dd58-17e7-4583-a987-174979d0ddf1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.21,
        "x": 0.73,
        "y": 0.49
      },
      "kind": "list",
      "text": "CR at 12 months; DoR; PFS",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "56524d24-420b-447a-b89c-59259a56ec13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.28,
        "x": 0.06,
        "y": 0.049
      },
      "kind": "list",
      "text": "Pathologically confirmed high-risk NMIBC; BCG-exposed patients must have had prior BCG therapy; Have all Ta/T1 disease resected prior to treatment",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1eb0fb1-573c-4244-a8d4-3085da2490e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "title",
      "text": "Phase 2 Cretostimogene Monotherapy Study for High-Risk, BCG-Exposed and BCG-Naïve NMIBC (Planned Study)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "becfed37-dca7-41b9-855a-ad30a580c1b1",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "9298744e-81d1-420a-ac82-c4c1426e5261",
      "evidence": "list/bullet: Pathologically confirmed high-risk NMIBC; BCG-exposed patients must have had prior BCG therapy; Have all Ta/T1 disease resected prior to treatment",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "b0a6e002-fccd-4acc-9cb7-950b6ab17143",
      "evidence": "The slide uses a three-column process flow to define the clinical trial methodology.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5790f76-8d5a-4a24-8439-7cae53e211ed",
      "evidence": "The loop is opened on slide 11 ('Bladder Cancer is a Significant Unmet Medical Need') and closed on slide 40 ('Intermediate-Risk & High-Risk Patients Need More Options to Get Better Outcomes').",
      "position": 0,
      "objective": "What are the consequences of not adopting Cretostimogene?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}